Pathologic response at the epicenter of the treatment decision-making process in Human Epidermal Receptor–Type 2 overexpressing (Her2+) Early Breast Cancer (EBC): Challenges and opportunities for financially-constrained healthcare systems

After more than two decades of intensive research, tremendous progress has been achieved in the management of Human Epidermal Receptor-2 overexpressing (Her2+) Early Breast Cancer (EBC). In the latest years, major clinical trials have explored the neoadjuvant scenario, in addition to the prognostic...

Descripción completa

Detalles Bibliográficos
Autor principal: Mano, Max S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Viewpoints and Debate
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724193/
https://www.ncbi.nlm.nih.gov/pubmed/33279792
http://dx.doi.org/10.1016/j.breast.2020.11.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724193/
https://www.ncbi.nlm.nih.gov/pubmed/33279792
http://dx.doi.org/10.1016/j.breast.2020.11.016

Ejemplares similares